184 related articles for article (PubMed ID: 21120485)
1. Serum levels of soluble CD163 in patients with systemic sclerosis.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Inoue Y; Ihn H
Rheumatol Int; 2012 Feb; 32(2):403-7. PubMed ID: 21120485
[TBL] [Abstract][Full Text] [Related]
2. Increased serum levels of soluble CD163 in patients with scleroderma.
Shimizu K; Ogawa F; Yoshizaki A; Akiyama Y; Kuwatsuka Y; Okazaki S; Tomita H; Takenaka M; Sato S
Clin Rheumatol; 2012 Jul; 31(7):1059-64. PubMed ID: 22453843
[TBL] [Abstract][Full Text] [Related]
3. High serum sCD163/sTWEAK ratio is associated with lower risk of digital ulcers but more severe skin disease in patients with systemic sclerosis.
Kowal-Bielecka O; Bielecki M; Guiducci S; Trzcinska-Butkiewicz B; Michalska-Jakubus M; Matucci-Cerinic M; Brzosko M; Krasowska D; Chyczewski L; Kowal K
Arthritis Res Ther; 2013; 15(3):R69. PubMed ID: 23800379
[TBL] [Abstract][Full Text] [Related]
4. Increased release of soluble CD163 by the peripheral blood mononuclear cells is associated with worse prognosis in patients with systemic sclerosis.
Bielecki M; Kowal K; Lapinska A; Chyczewski L; Kowal-Bielecka O
Adv Med Sci; 2013; 58(1):126-33. PubMed ID: 23640944
[TBL] [Abstract][Full Text] [Related]
5. Soluble CD163 as a Potential Biomarker in Systemic Sclerosis.
Frantz C; Pezet S; Avouac J; Allanore Y
Dis Markers; 2018; 2018():8509583. PubMed ID: 29805720
[TBL] [Abstract][Full Text] [Related]
6. CD163 expression is increased in the involved skin and sera of patients with systemic lupus erythematosus.
Nakayama W; Jinnin M; Makino K; Kajihara I; Makino T; Fukushima S; Sakai K; Inoue Y; Ihn H
Eur J Dermatol; 2012; 22(4):512-7. PubMed ID: 22576016
[TBL] [Abstract][Full Text] [Related]
7. Soluble CD163 is a potential biomarker in systemic sclerosis.
Matsushita T; Takehara K
Expert Rev Mol Diagn; 2019 Mar; 19(3):197-199. PubMed ID: 30657715
[No Abstract] [Full Text] [Related]
8. Association of CD163+ macrophages and local production of soluble CD163 with decreased lymphocyte activation in spondylarthropathy synovitis.
Baeten D; Møller HJ; Delanghe J; Veys EM; Moestrup SK; De Keyser F
Arthritis Rheum; 2004 May; 50(5):1611-23. PubMed ID: 15146432
[TBL] [Abstract][Full Text] [Related]
9. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
10. Association of the numbers of CD163(+) cells in lesional skin and serum levels of soluble CD163 with disease progression of cutaneous T cell lymphoma.
Sugaya M; Miyagaki T; Ohmatsu H; Suga H; Kai H; Kamata M; Fujita H; Asano Y; Tada Y; Kadono T; Okochi H; Sato S
J Dermatol Sci; 2012 Oct; 68(1):45-51. PubMed ID: 22884782
[TBL] [Abstract][Full Text] [Related]
11. Macrophage activation marker soluble CD163 and non-alcoholic fatty liver disease in morbidly obese patients undergoing bariatric surgery.
Kazankov K; Tordjman J; Møller HJ; Vilstrup H; Poitou C; Bedossa P; Bouillot JL; Clement K; Grønbaek H
J Gastroenterol Hepatol; 2015 Aug; 30(8):1293-300. PubMed ID: 25772748
[TBL] [Abstract][Full Text] [Related]
12. Elevated Serum Levels of Soluble CD163 in Polymyositis and Dermatomyositis: Associated with Macrophage Infiltration in Muscle Tissue.
Peng QL; Zhang YL; Shu XM; Yang HB; Zhang L; Chen F; Lu X; Wang GC
J Rheumatol; 2015 Jun; 42(6):979-87. PubMed ID: 25877505
[TBL] [Abstract][Full Text] [Related]
13. Usefulness of soluble CD163 as a biomarker for macrophage activation syndrome associated with systemic lupus erythematosus.
Nishino A; Katsumata Y; Kawasumi H; Hirahara S; Kawaguchi Y; Yamanaka H
Lupus; 2019 Jul; 28(8):986-994. PubMed ID: 31246559
[TBL] [Abstract][Full Text] [Related]
14. Monocyte/macrophage-derived soluble CD163: a novel biomarker in multiple myeloma.
Andersen MN; Abildgaard N; Maniecki MB; Møller HJ; Andersen NF
Eur J Haematol; 2014 Jul; 93(1):41-7. PubMed ID: 24612259
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of soluble CD163 as a specific marker of macrophage/monocyte activity in sarcoidosis patients.
Tanimura H; Mizuno K; Okamoto H
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Jul; 32(2):99-105. PubMed ID: 26278688
[TBL] [Abstract][Full Text] [Related]
16. Soluble CD163, a specific macrophage activation marker, is decreased by anti-TNF-α antibody treatment in active inflammatory bowel disease.
Dige A; Støy S; Thomsen KL; Hvas CL; Agnholt J; Dahlerup JF; Møller HJ; Grønbaek H
Scand J Immunol; 2014 Dec; 80(6):417-23. PubMed ID: 25346048
[TBL] [Abstract][Full Text] [Related]
17. Utility of Macrophage-activated Marker CD163 for Diagnosis and Prognosis in Pulmonary Tuberculosis.
Suzuki Y; Shirai M; Asada K; Miwa S; Karayama M; Nakamura Y; Inui N; Shirai T; Hayakawa H; Baba S; Suda T
Ann Am Thorac Soc; 2017 Jan; 14(1):57-64. PubMed ID: 27684274
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD163 is an indicator of liver inflammation and fibrosis in patients chronically infected with the hepatitis B virus.
Dultz G; Gerber L; Farnik H; Berger A; Vermehren J; Pleli T; Zeuzem S; Piiper A; Kronenberger B; Waidmann O
J Viral Hepat; 2015 Apr; 22(4):427-32. PubMed ID: 25181653
[TBL] [Abstract][Full Text] [Related]
19. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
20. Serum neopterin and soluble CD163 as markers of macrophage activation in paracetamol (acetaminophen)-induced human acute liver injury.
Craig DG; Lee P; Pryde EA; Hayes PC; Simpson KJ
Aliment Pharmacol Ther; 2013 Dec; 38(11-12):1395-404. PubMed ID: 24138337
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]